↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Burman P) ;pers:(Burman Joachim 1974)"

Sökning: WFRF:(Burman P) > Burman Joachim 1974

Resultat 1-10 av 23

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Alping, P, et al. (författare) Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location 2017 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : SAGE PUBLICATIONS LTD. - 1352-4585 .- 1477-0970. ; 23, s. 714-714 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
2.	Alping, P, et al. (författare) Rituximab in multiple sclerosis; data from the swedish MS registry. 2016 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : SAGE PUBLICATIONS LTD. - 1352-4585 .- 1477-0970. ; 22, s. 49-49 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
3.	Demirbuker, SS, et al. (författare) A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) 2018 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24, s. 701-702 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
4.	Demirbuker, SS, et al. (författare) A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4) 2018 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24, s. 922-923 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
5.	Falt, A, et al. (författare) A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3) 2018 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24, s. 706-707 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
6.	Falt, A, et al. (författare) A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2) 2018 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24, s. 696-697 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
7.	Kagstrom, S, et al. (författare) A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1) 2018 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24, s. 699-700 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
8.	Kagstrom, S, et al. (författare) Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile 2018 Ingår i: MULTIPLE SCLEROSIS JOURNAL. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 24, s. 927-928 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
9.	Tedeholm, Helen, 1978, et al. (författare) Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. 2022 Ingår i: Multiple Sclerosis and Related Disorders. - : Elsevier. - 2211-0348 .- 2211-0356. ; 68 Tidskriftsartikel (refereegranskat)abstract BACKGROUND: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) has been associated with reduced relapse rates and accumulation of disability. However, studies examining impact of DMT on risk of transition to secondary progressive MS (SPMS) leveraging population-based nationwide data are still rare. Here, we determine the population incidence of conversion to SPMS using two consecutive nation-wide cohorts, one immediately before and one after the introduction of DMT in Sweden.METHODS: We included two consecutive population cohorts of relapsing-remitting MS (RRMS) from the Swedish national MS register for the periods 1975-1994 (n = 2161), before DMT availability, and 1995-2011 (n = 3510), in which DMTs, mainly first generation DMT (injectables), became available and eventually were used by 70% of patients. We explored the risk of transition to SPMS as a calendar year function encompassing the two cohorts. In addition, we determined the incidence of transition to SPMS through age strata below and above 50 years in untreated and treated patient subgroups.RESULTS: The risk of conversion to SPMS (adjusted for current age, current time since onset, calendar year and sex) was significantly lower in the second compared with the first population cohort (hazard ratio 0.58; CI 0.48, 0.70). The risk of SPMS conversion per calendar year decreased by 2.6% annually (p < 0.001) after 1995. The risk of SPMS conversion increased with age until age 50. Thereafter, it was unchanged or decreased among those with early MS onset age (<35 years), but continued to increase with onset at higher age, with similar trends in treated and untreated subgroups.CONCLUSION: The incidence of SPMS conversion significantly decreased at the population level after introduction of first generation DMTs by 1995. DMT efficiency was confirmed by a downward turn of the annual trajectory of the risk of SPMS conversion after 1995. An onset age determined pattern of variable SPMS incidence in higher age appeared in both treated and untreated strata. While first generation DMT delayed conversion to SPMS, their long-term effect was only moderate.
10.	Burman, Joachim, 1974-, et al. (författare) Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis : a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) 2017 Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 0268-3369 .- 1476-5365. ; 52:8, s. 1133-1137 Tidskriftsartikel (refereegranskat)abstract Autologous hematopoietic stem cell transplantation (aHSCT) is a promising therapy for multiple sclerosis (MS), which has mainly been used in adults. The purpose of this study was to investigate efficacy and adverse events of aHSCT in the treatment of children with MS using data from the European Society for Blood and Marrow Transplantation registry. Twenty-one patients with a median follow-up time of 2.8 years could be identified. PFS at 3 years was 100%, 16 patients improved in expanded disability status scale score and only 2 patients experienced a clinical relapse. The procedure was generally well tolerated and only two instances of severe transplant-related toxicity were recorded. There was no treatment-related mortality, although one patient needed intensive care. aHSCT may be a therapeutic option for children with disease that does not respond to standard care.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-10 av 23

Avgränsa träffmängd

Typ av publikation: konferensbidrag (14); tidskriftsartikel (9)

Typ av innehåll: övrigt vetenskapligt/konstnärligt (16); refereegranskat (7)

Författare/redaktör: Burman, Joachim,... (23)Ta bort avgränsningen; Nilsson, P. (17); Piehl, F (17); Lycke, J (16); Hillert, J (15); Olsson, T (15); visa fler...; Martin, C (15); Svenningsson, A (13); Landtblom, Anne-Mari ... (11); Gunnarsson, M (7); Berglund, A. (5); Johansson, S (3); Badoglio, M (3); Saccardi, R (3); Farge, D (3); Fink, K (3); Kazmi, M (2); Alping, P (2); Salzer, J (2); Wang, Y. (1); Svenningsson, P (1); Larsson, Anders (1); Haas, J (1); Zetterberg, Henrik, ... (1); Johansson, Helena, 1 ... (1); Bergquist, Jonas (1); Emami Khoonsari, Pay ... (1); Shevchenko, Ganna (1); Kultima, Kim (1); Abujrais, Sandy (1); Åkerfeldt, Torbjörn (1); Lycke, Jan, 1956 (1); Carlson, Kristina (1); Ljungman, P (1); Paucar, M (1); Nyholm, Dag (1); Constantinescu, Radu ... (1); Andersen, Oluf, 1941 (1); Spjuth, Ola, Docent, ... (1); Del Papa, N (1); Labopin, M (1); Alexander, T (1); Ouyang, J (1); Bader, P (1); Corbacioglu, S (1); Muraro, PA (1); Greco, R (1); Snarski, E (1); Snowden, JA (1); Sundström, Peter (1); visa färre...

Lärosäte: Uppsala universitet (23); Karolinska Institutet (20); Göteborgs universitet (3); Umeå universitet (1); Örebro universitet (1); Linköpings universitet (1); visa fler...; Lunds universitet (1); visa färre...

Språk: Engelska (23)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (23); Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy